Late last week, the Centers for Medicare and Medicaid Services (CMS) finalized its proposal to pay for biosimilars under Medicare Part B the same way it pays for generic drugs. The decision reflects the fact that biologics and biosimilars are made of large, complex molecules and cannot be exact copies of one another, as is the case with brand and generic small-molecule drugs. Politico’s website has the story on their Prescription Pulse page. The rule is available here.
Last Updated on May 7, 2020 by Aimed Alliance
